EVOTEC NEUROSCIENCES
Evotec Neurosciences GmbH engages in the discovery and development of small molecule drugs.
EVOTEC NEUROSCIENCES
Social Links:
Industry:
Biopharma Biotechnology Health Care Neuroscience
Founded:
1999-05-01
Address:
Hamburg, Hamburg, Germany
Country:
Germany
Total Employee:
11+
Status:
Active
Contact:
+49 40 560 81 0
Total Funding:
25 M EUR
Similar Organizations
Galapagos
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel.
Morria Biopharmaceuticals
Morria Biopharmaceuticals engages in the discovery and development of multi-functional anti-inflammatory drugs.
Current Employees Featured
Founder
Investors List
Ventech
Ventech investment in Series A - Evotec Neurosciences
Techno Venture Management
Techno Venture Management investment in Series A - Evotec Neurosciences
Star Ventures
Star Ventures investment in Series A - Evotec Neurosciences
3i Plc
3i Plc investment in Series A - Evotec Neurosciences
MVM Life Science Partners
MVM Life Science Partners investment in Series A - Evotec Neurosciences
More informations about "Evotec Neurosciences"
Neuroscience & Pain - Evotec
Empowering Innovation: Evotec’s Trailblazing Neuroscience Drug Discovery. Our world-class platform for ion channel drug discovery includes electrophysiology and pharmacology …See details»
Together for Medicines That Matter - Evotec
Evotec is a global biotechnology company committed to advancing drug discovery & development together with our partners for medicines that matter. Together for Medicines That Matter. Diseases impact everyone. Unmet medical needs are …See details»
Evotec Neurosciences - Crunchbase Company Profile & Funding
Evotec Neurosciences closed its last funding round on Apr 2, 2004 from a Series A round. Who are Evotec Neurosciences 's competitors? Alternatives and possible competitors to Evotec …See details»
Evotec Announces Progress in Neuroscience Collaboration with …
Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases.See details»
Evotec Neurosciences Company Profile 2024: Valuation, Investors ...
Evotec Neurosciences was founded in 1999. Where is Evotec Neurosciences headquartered? Evotec Neurosciences is headquartered in Hamburg, Germany. What is the size of Evotec …See details»
Evotec Neurosciences GmbH - Hamburg, Germany - bionity.com
Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas …See details»
Evotec and Bristol Myers Squibb Enter Licence Agreement within ...
Jul 11, 2023 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that Bristol Myers Squibb Company (NYSE:BMY) has …See details»
BMS upgrades Evotec neurology alliance, now worth up to $4bn
Mar 28, 2023 Bristol-Myers Squibb has expanded a long-running alliance with Evotec once again, paying another $50 million upfront to deepen their collaboration on drugs to treat …See details»
Evotec Neurosciences and Evotec OAI Enter into Joint Drug …
Evotec Neurosciences (ENS), employs 26 people at its main site in Hamburg, Germany, and subsidiary in Zurich, Switzerland. The company is dedicated to developing better therapeutic …See details»
Evotec Achieves Further Progress in Neuroscience Collaboration …
Dec 16, 2022 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has achieved further …See details»
Evotec-Bristol Myers Squibb Partnership Hits $25M Milestone in ...
Aug 9, 2024 Evotec SE has received a $25 million milestone payment from Bristol Myers Squibb, marking further progress in their strategic partnership focused on advancing …See details»
Evotec, BMS Advance Strategic Neuroscience Pact
Aug 8, 2024 Evotec SE has made progress under a strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programs.Evotec …See details»
Evotec and Bristol Myers Squibb enter licence agreement within ...
Jul 11, 2023 Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “This licence agreement will further bolster our joint pipeline of programmes targeting several …See details»
Evotec announces progress in strategic neuroscience partnership …
Jan 7, 2024 Evotec SE today announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience …See details»
Evotec Announces Progress in Strategic Neuroscience Partnership …
Aug 8, 2024 Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of …See details»
BMS re-ups legacy neurodegeneration deal with Evotec - Fierce …
Mar 28, 2023 Evotec uses its modality-agnostic precision medicine platforms to develop clinical candidates. BMS Senior Vice President of Neuroscience Richard Hargreaves, Ph.D., said in …See details»
Innovations in Oligonucleotide Synthesis for Rna-Targeted Drug ...
Jul 17, 2024 Evotec is a leader in integrated end-to-end Research and Development and has built substantial drug discovery expertise and technical capabilities that can drive new …See details»
Evotec Achieves Programme Designation in Neuroscience …
Apr 8, 2022 The neuroscience collaboration between Evotec and Bristol Myers Squibb aims to identify disease-modifying treatments for a broad range of neurodegenerative diseases. …See details»
Evotec expands neuroscience collaboration with Bristol Myers …
Evotec expands neuroscience collaboration with Bristol Myers Squibb to ... ... Science PoolSee details»